Navigation Links
DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
Date:5/3/2012

tive drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER®, ORADUR®, TRANSDUR® and ELADUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR, TRANSDUR-Sufentanil and Relday are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement The statements in this press release regarding the potential bioavailability studies for REMOXY, potential regulatory meetings and submissions for REMOXY and POSIDUR, anticipated clinical trials (including timing and results) for Relday and our other drug candidates, the potential benefits and uses of our drug candidates, collaborations with third parties and potential business development activities are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of adverse decisions by regulatory agencies, including rejection of meeting requests, requests for additional information or product non-approval, delays and additional costs due to requirements imposed by regulatory agencies, potential adverse effects arising from the testing or use of our drug candidates, the potential failure of our clinical trials to meet
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
2. DURECT Corporation Invites You to Join Its Fourth Quarter 2011 Earnings Conference Call
3. DURECT to Participate in Upcoming Healthcare Conferences
4. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
5. DURECT Corporation Invites You to Join its Third Quarter 2011 Earnings Conference Call
6. DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR® (BESST)
7. DURECT Corporation to Participate in Upcoming Healthcare Conferences
8. DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
9. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
10. DURECT to Present at the Jefferies Healthcare Conference
11. DURECT Announces Resignation of Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Fla. , Dec. 19, 2014 Breckenridge ... a multi-product agreement with MSN Laboratories Pvt. Ltd. ( ... MSN expect to commercialize several new ANDAs.  Under the ... supply the products exclusively to Breckenridge for the U.S. ... under its label.  Breckenridge and MSN have agreed to ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, 2014 /PRNewswire/ ...  Sorrento), an oncology company developing new treatments for ... privately-held immuno-oncology company developing proprietary Neukoplast ® ... announced today that the companies have entered into ... CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for the treatment ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... the United States will increase to a ... be primarily driven by expansion in the large direct ... devices will be increasingly adopted due to the advantages ... Other key findings from Decision Resources Group,s coverage ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3
... 14, 2011 LifeVantage Corporation (OTCBB: LFVN), the ... revenue for its third fiscal quarter of 2011 of approximately ... or 35% over net revenue of $7.4 million for the ... an approximate $7.3 million or 270% increase in net revenue ...
... CITY, Iowa, April 14, 2011 Ron Van ... Natural Science , announced that research conducted at Iowa ... in DiaGel eliminates bacteria on contact. ... microdilution testing, disk diffusion, and traditional microbiological plating.  Through ...
Cached Medicine Technology:LifeVantage Announces Preliminary Third Quarter 2011 Revenue 2Van Beek Natural Science's Patented Active Compound in DiaGel Offers one Dose Natural Cure for Pet Bacterial Diarrhea 2
(Date:12/22/2014)... 2014 Xarelto Lawsuit News : ... judges has granted a request to centralize pending and ... Court, Eastern District of Louisiana. The U.S. Judicial Panel ... 12 to transfer over 50 Xarelto cases–21 lawsuits and ... Louisiana court for consolidation under U.S. District Judge Eldon ...
(Date:12/22/2014)... Farmers Branch, TX (PRWEB) December 22, 2014 ... the revolutionary work glove with many useful features. Customers ... savings and can have the new gloves delivered to ... manufactures work gear and hand tools that incorporate heavy ... Pro Utility Magnetic Glove allows workers to store metal ...
(Date:12/22/2014)... Christmas is days away, and last minute gifts may ... that will please: the Sublime Gift Card . , ... up to $350," says Kathy Heshelow, founder of Sublime ... array of skin care products and Skin Brushes." , The ... , Gift delivery past shipping deadlines, or those last minute ...
(Date:12/22/2014)... NAPW honors Cheryl ... the Year. She is recognized with this prestigious distinction ... networking organization of professional women in the country, spanning ... Professional Women is a vibrant networking community with over ... Kreider is passionate and committed to best practices that ...
(Date:12/22/2014)... The NLN’s 2015 Leadership ... this month. Faculty have been selected through competitive ... fast-tracked for administrative leadership roles within their academic ... Simulation Educators, featuring a curriculum uniquely devised for ... , Twenty nurse educators were chosen for ...
Breaking Medicine News(10 mins):Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3
... FAIRFAX, Va., Sept. 25 The American Society,for ... version of,its brochure Radiation Therapy for Gynecologic Cancers. ... useful information on the,different types of radiation therapy ... on the potential side effects and how to ...
... Australia have shown that positron emission tomography (PET) ... useful than mammography and ultrasound in predicting a ... patients ultimate likelihood of survival. , In research ... (ECCO 14) in Barcelona, Dr Vinod Ganju reported ...
... new song has helped scientists open a new avenue of ... there is currently no cure or even a treatment to ... in the Journal of Clinical Investigation, scientists at the University ... someday be used to treat the disease. The team used ...
... found that the breast cancer susceptibility gene, BRCA1, plays a ... can it be used to predict outcome for patients with ... tool in choosing the best therapy for them. , Dr ... 14) in Barcelona, that analysis of the expression of five ...
... gliomas (BSGs) are rare but can be very difficult ... survival rates. However, a team of Spanish researchers have ... (I/C) produced rapid clinical responses and shrank the tumours ... enrolled in a clinical trial. , Dr Jaume Mora ...
... Researchers in The Netherlands have developed a method of ... likely to have their disease recur after surgery and ... chemotherapy. , Led by Professor Rob Tollenaar at Leiden ... at The Netherlands Cancer Institute, they have analysed for ...
Cached Medicine News:Health News:Updated Brochure on Gynecologic Cancer Treatments Now Available 2Health News:PET scans can accurately detect a breast tumor's response to chemotherapy 2Health News:PET scans can accurately detect a breast tumor's response to chemotherapy 3Health News:Stem cells show promise for treating Huntington's disease 2Health News:Stem cells show promise for treating Huntington's disease 3Health News:Stem cells show promise for treating Huntington's disease 4Health News:Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer 2Health News:Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer 3Health News:New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas 2Health News:Molecular profiling can accurately predict survival in colon cancer patients 2Health News:Molecular profiling can accurately predict survival in colon cancer patients 3
This advanced digital monitor detects the appearance of an irregular heartbeat during measurement and gives a warning signal with your reading. An irregular heartbeat may cause or indicate cardiovasc...
... Through its unique and patented ... wires and trunk cables between patients ... monitors, allowing freedom of movement throughout ... technology, the LifeSync(R) System employs two-way ...
Inquire...
... STA Compact is ... access coagulation analyser for ... latex based .coagulation tests.The ... loading of primary tubes, ...
Medicine Products: